TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07492680: A Phase 2 Open-Label, Multi-Center Study of Navlimetostat (BMS-986504) as Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (Mount

Sponsor: Bristol-Myers Squibb · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 254 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$2,679,600

Rescue Site Savings

+$1,755,600

Unlock Full NCT07492680 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07492680 Rescue Dossier →